Synthesis and characterization of some novel diaryl urea derivatives bearing quinoxalindione moiety

Sedighe Sadeghian-Rizi, Ghadamali Khodarahmi, Amirhossein Sakhteman, Ali Jahanian-Najafabadi, Mahboubeh Rostami, Mahmoud Mirzaei, Farshid Hassanzadeh


Diaryl urea derivatives have exhibited a broad spectrum of biochemical effects and pharmaceutical applications. Several diaryl urea derivatives such as sorafenib, regorafenib, linifanib, and tivozanib and lenvatinib are in clinical trial or clinical use. Therefore, development of small molecules within the diaryl urea scaffold with the ability of binding to variety of enzymes and receptors in the biological system are an interesting topic for researchers. Sorafenib as a diaryl urea derivative is a well-known anticancer agent. Corresponding to available information about biological activities of quinoxaline moieties, based on sorafenib scaffold, several structures were designed by replacement of pyridyl carboxamide group                        of sorafenib with quinoxalindione moiety. A total of 14 novel compounds in 7 synthetic steps                          were synthesized. Briefly, the amino group of p-aminophenol was first protected followed by O-arylation of 4-acetamidophenol with 5-chloro-2-nitroaniline to provide 5-(4-acetamidophenoxy)-2-nitroaniline. Reduction of the nitro group of 5-(4-acetamidophenoxy)-2-nitroaniline and cyclization of diamine                    N-(4-(3,4-diaminophenoxy) phenyl) acetamides  with oxalic acid afforded compound N-(4-((2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-6-yl)oxy)phenyl) acetamides which on deacetylation gave compounds                6-(4-aminophenoxy) quinoxaline-2,3 (1H, 4H)-diones. Then resultant compounds, 6-(4-aminophenoxy) quinoxaline-2,3 (1H, 4H)-diones were reacted by appropriate isocyanates/ carbamates to give the target compounds 1-(4-((2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-6-yl)oxy)phenyl)-3-phenylureas. The structures of compounds confirmed by proton nuclear magnetic resonance (1H NMR), mass spectrum and Fourier transform infrared (FT-IR).


Diaryl urea; Quinoxalindione; Sorafenib derivatives

Full Text:



Kim HJ, Cho HJ, Kim H, El-Gamal MI, Oh CH, Lee SH, et al. New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line. Bioorg Med Chem Lett. 2012;22(9):3269-3273.

Zambon A, Ménard D, Suijkerbuijk BMJM, Niculescu-Duvaz I, Whittaker S, et al. Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors. J Med Chem. 2010;53(15):5639-5655.

Zhao CR, Wang RQ, Li G, Xue XX, Sun CJ, Qu XJ, et al. Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines. Bioorg Med Chem Lett. 2013;23(7):1989-1992.

Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12(24):7271-7278.

Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223-2240.

Fala L. Lenvima (Lenvatinib), a multireceptor tyrosine kinase inhibitor, approved by the fda for the treatment of patients with differentiated thyroid cancer. American health and drug benefits. 2015;8(Spec Feature):176.

Wong HH, Eisen T. Tivozanib for the treatment of metastatic renal cancer. Expert Rev Anticancer Ther. 2013;13(6):649-660.

Marlow M, Al-Ameedee M, Smith T, Wheeler S, Stocks MJ. Linifanib–a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator. Chem Commun. 2015;51(29):6384-6387.

Niculescu-Duvaz I, Roman E, Whittaker SR, Friedlos F, Kirk R, Scanlon IJ, et al. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem. 2006;49(1):407-416.

Ramurthy S, Subramanian S, Aikawa M, Amiri P, Costales A, Dove J, et al. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J Med Chem. 2008;51(22):7049-7052.

Wang K, Li Y, Zhang L-J, Chen X-G, Feng Z-Q. Synthesis and in vitro cytotoxic activities of sorafenib derivatives. Chin Chem Lett. 2014;25(5):702-704.

Wu C, Wang M, Tang Q, Luo R, Chen L, Zheng P, et al. Design, synthesis, activity and docking study of sorafenib analogs bearing sulfonylurea unit. Molecules. 2015;20(10):19361-19371.

Yao J, Chen J, He Z, Sun W, Xu W. Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents. Bioorg Med Chem. 2012;20(9):2923-2929.

Niculescu-Duvaz D, Gaulon C, Dijkstra HP, Niculescu-Duvaz I, Zambon A, Ménard D, et al. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J med chem. 2009;52(8):2255-2264.

Zambon A, Ménard D, Suijkerbuijk BM, Niculescu-Duvaz I, Whittaker S, Niculescu-Duvaz D, et al. Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors. J Med Chem. 2010;53(15):5639-5655.

Corona P, Carta A, Loriga M, Vitale G, Paglietti G. Synthesis and in vitro antitumor activity of new quinoxaline derivatives. Eur J Med Chem. 2009;44(4):1579-1591.

Grande F, Aiello F, Grazia OD, Brizzi A, Garofalo A, Neamati N. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem. 2007;15(1):288-294.

Tanimori S, Nishimura T, Kirihata M. Synthesis of novel quinoxaline derivatives and its cytotoxic activities. Bioorg Med Chem Lett. 2009;19(15):4119-4121.

Zarranz B, Jaso A, Aldana I, Monge A. Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives. Bioorg Med Chem. 2004;12(13):3711-3721.

Kotra VP, Karakavalasa; Vasanthi, R. Synthesis, characterization and pharmacological evaluation of some novel quinoxaline derived chalcones. Der Pharma Chemica. 2013;5(4):301-307.

Noorulla S, Sreenivasulu N, Khan A, Sayeed A. Antibacterial activity of novel substituted quinoxaline heterocycles. Pharmanest. 2011;2(2-3):229-238.

Sadeghian-Rizi S, Sakhteman A, Hassanzadeh F. A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors. Res Pharm Sci. 2016;11(6):445-453.

Sastry C, Marwah P, Marwah A, Rao G. Synthesis and Biological Activity of Some New N‐Arylcarbamoyl and N‐Arylthiocarbamoyl Hydrazinoquinoxalin‐2‐ones. ChemInform. 1990;21(6):885-887.

Yoo HW, Lee YS, Eun Suh M, Kim DJ, Park SW. Cytotoxic effects of quinoxaline derivatives on human cancer cell lines. Archiv Der Pharmazie. 1998;331(10):331-333.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.